HALOZYME (NASDAQ: HALO) director sells 1,625 shares in Rule 10b5-1 trade

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton sold 1,625 shares of common stock in an open-market transaction at $63.48 per share. After this sale, she directly holds 38,498 shares. The filing notes the sale was made under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance.

Insights

Small, pre-planned sale by a director; routine and limited in size.

Director Bernadette Connaughton sold 1,625 shares of HALOZYME THERAPEUTICS, INC. common stock at $63.48 per share. She retains 38,498 shares after this transaction, so the sale represents only a small portion of her direct holdings.

The transaction was executed under a written Rule 10b5-1 trading plan, meaning it was pre-arranged rather than timed opportunistically. Combined with the modest scale relative to her remaining stake, this points to a routine liquidity move rather than a thesis-changing signal.

Insider Trade Summary 10b5-1

Net Seller: 1,625 shares ($103,155)

Net Sell 1 txn

Insider Connaughton Bernadette

Role null

Sold 1,625 shs ($103K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,625	$63.48	$103K

Holdings After Transaction: Common Stock — 38,498 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 1,625 shares Sale price: $63.48 per share Shares held after transaction: 38,498 shares

3 metrics

Shares sold 1,625 shares Open-market sale on May 1, 2026

Sale price $63.48 per share Price for HALO common stock in reported sale

Shares held after transaction 38,498 shares Director’s direct holdings following the sale

Key Terms

Rule 10b5-1, Form 4, open-market sale

3 terms

Rule 10b5-1 regulatory

"a written trading plan adopted by the Reporting Person ... in accordance with Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Form 4 regulatory

"The sales reported on this Form 4 were made pursuant to a written trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

05/05/2026 - 05:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Connaughton Bernadette

(Last)

(First)

(Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/01/2026		S⁽¹⁾		1,625	D	$63.48	38,498	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did HALO (HALOZYME THERAPEUTICS) report in this Form 4?

The Form 4 reports that director Bernadette Connaughton sold 1,625 shares of HALOZYME THERAPEUTICS common stock. The shares were sold in an open-market transaction at a price of $63.48 per share, reflecting a modest, disclosed insider sale.

How many HALO shares did director Bernadette Connaughton retain after the reported sale?

After selling 1,625 shares, director Bernadette Connaughton directly holds 38,498 shares of HALOZYME THERAPEUTICS common stock. This indicates that the transaction reduced, but did not significantly change, her overall direct equity position in the company.

At what price did the HALO director sell shares in the reported Form 4 transaction?

The reported sale by HALOZYME THERAPEUTICS director Bernadette Connaughton occurred at $63.48 per share. This price applies to the 1,625 common shares sold in the open-market transaction disclosed in the Form 4 insider filing.

Was the HALO Form 4 insider sale made under a Rule 10b5-1 trading plan?

Yes. A footnote states the sales were made under a written trading plan adopted in accordance with Rule 10b5-1. Such plans pre-schedule trades, indicating this sale was planned in advance rather than timed in response to short-term market movements.

Does the HALO insider sale in this Form 4 appear routine or unusual in scale?

The sale appears routine in scale. Director Bernadette Connaughton sold 1,625 shares while retaining 38,498 shares. Combined with the use of a Rule 10b5-1 trading plan, the filing suggests a modest, pre-planned transaction rather than a large position change.